Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy

被引：20

作者：

Grebely, Jason ^{[1
]}

Conway, Brian ^{[2
]}

Cunningham, Evan B. ^{[1
]}

Fraser, Chris ^{[3
]}

Moriggia, Alberto ^{[4
]}

Gane, Ed ^{[5
]}

Stedman, Catherine ^{[6
,7
]}

Cooper, Curtis ^{[8
]}

Castro, Erika ^{[9
]}

Schmid, Patrick ^{[10
]}

Petoumenos, Kathy ^{[1
]}

Hajarizadeh, Behzad ^{[1
]}

Marks, Phillipa ^{[1
]}

Erratt, Amanda ^{[1
]}

Dalgard, Olav ^{[11
]}

Lacombe, Karine ^{[12
]}

Feld, Jordan J. ^{[13
]}

Bruneau, Julie ^{[14
]}

Daulouede, Jean-Pierre ^{[15
]}

Powis, Jeff ^{[16
]}

Bruggmann, Philip ^{[17
]}

Matthews, Gail V. ^{[1
]}

Kronborg, Ian ^{[18
]}

Shaw, David ^{[19
]}

Dunlop, Adrian ^{[20
]}

Hellard, Margaret ^{[21
]}

Applegate, Tanya L. ^{[1
]}

Crawford, Sione ^{[22
]}

Dore, Gregory J. ^{[1
]}

机构：

[1] UNSW, UNSW Sydney, Kirby Inst, Wallace Wurth Bldg, Sydney, NSW 2052, Australia

[2] Vancouver Infect Dis Ctr, Vancouver, BC, Canada

[3] Coolaid Community Hlth Ctr, Victoria, BC, Canada

[4] Fdn Epatoctr Ticino, Lugano, Switzerland

[5] Auckland Hosp, Auckland, New Zealand

[6] Christchurch Hosp, Christchurch, New Zealand

[7] Univ Otago, Christchurch, New Zealand

[8] Ottawa Hosp Res Inst, Ottawa, ON, Canada

[9] CHU Vaudois, Lausanne, Switzerland

[10] Kantonsspital St Gallen, St Gallen, Switzerland

[11] Akershus Univ Hosp, Oslo, Norway

[12] Sorbonne Univ, Hop St Antoine, INSERM, UMR S1136, Paris, France

[13] Toronto Gen Hosp, Toronto, ON, Canada

[14] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[15] Csapa Bizia, Bayonne, France

[16] South Riverdale Community Hlth Ctr, Toronto, ON, Canada

[17] Arud Ctr Addict Med, Zurich, Switzerland

[18] Footscray Hosp, Footscray, Vic, Australia

[19] Royal Adelaide Hosp, Adelaide, SA, Australia

[20] Newcastle Pharmacotherapy Serv, Newcastle, NSW, Australia

[21] Burnet Inst, Melbourne, Vic, Australia

[22] Harm Reduct Victoria, Melbourne, Vic, Australia

来源：

INTERNATIONAL JOURNAL OF DRUG POLICY | 2018年 / 62卷

基金：

英国医学研究理事会;

关键词：

Hepatitis C; Treatment; PWID; Drug use; Injecting drug users; DAA; HEPATITIS-C VIRUS; SUSTAINED VIROLOGICAL RESPONSE; ACTING ANTIVIRAL AGENTS; TERM CLINICAL-OUTCOMES; 1-INFECTED PATIENTS; RISK-FACTORS; OPEN-LABEL; INFECTION; EFFICACY; SAFETY;

D O I：

10.1016/j.drugpo.2018.10.004

中图分类号：

R194 [卫生标准、卫生检查、医药管理];

学科分类号：

摘要：

Background: Direct-acting antiviral therapy for hepatitis C virus (HCV) infection is safe and effective, but there are little data among people who have recently injected drugs. This study evaluated the efficacy, and safety of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin for chronic HCV genotype (G) 1 among people with recent injecting drug use and/or receiving OST. Methods: D3FEAT is an international open-label study that recruited treatment-naive participants with recent injecting drug use (previous 6 months) and/or receiving OST with chronic HCV G1 infection between June 2016 and February 2017 in seven countries. Participants received paritaprevir/ritonavir, ombitasvir, dasabuvir with (Gla) or without ribavirin (Gib) administered twice daily in a one-week electronic blister pack (records timing of each dose) for 12 weeks. The primary endpoint was undetectable HCV RNA 12 weeks post-treatment (SVR12). Results: Among 87 participants (median age 48 years), 23% were female, 8% had cirrhosis, and 90% had Gla. Overall, 71% were receiving OST, 61% injected in the previous six months, 45% injected in the previous month, and 15% injected > daily. Treatment completion was 97% (84 of 87). There were no virological breakthroughs, but three discontinuations (loss to follow-up, n = 1; non-adherence, n = 1; incarceration, n = 1). SVR was 91% (79 of 87, 95% CI, 83%-96%). Five participants who completed treatment did not have SVR (loss to follow-up, n = 1; death, n = 1; virologic relapse, n = 3). Drug use prior to and during treatment did not impact SVR12. Treatment-related adverse events were observed in 46 (53%) patients (six grade 3, no grade 4). Five (6%) patients had at least one serious adverse event (two possibly/probably related to therapy; nausea and myoclonus). Two cases of reinfection were observed. Conclusion: Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for 12 weeks is effective among people with HCV genotype 1 with recent injecting drug use and/or receiving OST.

引用

页码：94 / 103

页数：10

共 50 条

[1] Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4
Leung, Daniel H.
Wirth, Stefan
Yao, Betty B.
Viani, Rolando M.
Gonzalez-Peralta, Regino P.
Jonas, Maureen M.
Lobritto, Steven J.
Narkewicz, Michael R.
Soka, Etienne
Fortuny, Claudia
Hsu, Evelyn K.
Del Valle-Segarra, Antonio
Zha, Jiuhong
Larsen, Lois
Liu, Li
Shuster, Diana L.
Cohen, Daniel E.
Rosenthall, Philip
HEPATOLOGY COMMUNICATIONS, 2018, 2 (11) : 1311 - 1319
[2] Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin
Feld, Jordan J.
Bernstein, David E.
Younes, Ziad
Van Vlierberghe, Hans
Larsen, Lois
Tatsch, Fernando
Ferenci, Peter
LIVER INTERNATIONAL, 2018, 38 (09) : 1571 - 1575
[3] Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection
Martinello, M.
Bhagani, S.
Gane, E.
Orkin, C.
Cooke, G.
Dore, G. J.
Petoumenos, K.
Applegate, T. L.
Tu, E.
Marks, P.
Pagani, N.
Grebely, J.
Nelson, M.
Matthews, G. V.
JOURNAL OF VIRAL HEPATITIS, 2018, 25 (10) : 1180 - 1188
[4] PHARMACOKINETICS OF PARITAPREVIR, OMBITASVIR, DASABUVIR, RITONAVIR AND RIBAVIRIN IN SUBJECTS WITH HCV GENOTYPE 1 INFECTION IN PHASE 3 STUDIES
Mensing, S.
Sharma, S.
Eckert, D.
Polepally, A.
Khatri, A.
Podsadecki, T.
Awni, W.
Menon, R.
Dutta, S.
JOURNAL OF HEPATOLOGY, 2015, 62 : S644 - S644
[5] Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection
Emma D. Deeks
Drugs, 2015, 75 : 1027 - 1038
[6] Hepatic encephalopathy in the course of anti-HCV therapy with paritaprevir/ritonavir, ombitasvir, dasabuvir and ribavirin
Fabrizio, Claudia
Saracino, Annalisa
Milella, Michele
Resta, Francesco
Angarano, Gioacchino
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2016, 48 (01) : 115 - 116
[7] Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection
Deeks, Emma D.
DRUGS, 2015, 75 (09) : 1027 - 1038
[8] Ombitasvir/Paritaprevir/r and Dasabuvir with Ribavirin for HCV Genotype 1 Patients with Decompensated Cirrhosis
Mantry, Parvez S.
Hanson, John
Trinh, Roger
Ramji, Alnoor
Fredrick, Linda
Abunimeh, Manal
Canizaro, Leticia
Liu, Li
Shulman, Nancy
Gordon, Stuart C.
HEPATOLOGY, 2015, 62 : 568A - 569A
[9] Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients
Khatri, Amit
Mensing, Sven
Podsadecki, Thomas
Awni, Walid
Menon, Rajeev
Dutta, Sandeep
CLINICAL DRUG INVESTIGATION, 2016, 36 (08) : 625 - 635
[10] Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients
Amit Khatri
Sven Mensing
Thomas Podsadecki
Walid Awni
Rajeev Menon
Sandeep Dutta
Clinical Drug Investigation, 2016, 36 : 625 - 635

← 1 2 3 4 5 →